Drug Trial Radar · NCT00596752
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Last checked: Nov 19, 2026Latest source record: Apr 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
840
Actual
Start
Mar 2004
Primary completion
May 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- UCB BIOSCIENCES GmbHUCB
- Sponsor type
- Industry
- Collaborators
- Aptiv Solutions
- First posted
- Jan 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients suffering from PAOD stage IV.
Conditions
- Peripheral Arterial Occlusive Disease
Interventions
AlprostadilDrug
* Active Substance: Prostaglandin E1 * Pharmaceutical Form: solution for infusion * Concentration: 40 μg b.d. * Route of Administration: intravenous infusion
PlaceboOther
* Active Substance: Lactose * Pharmaceutical Form: solution for infusion * Concentration: 40 μg b.d. * Route of Administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug TreatmentTime frame: At 12 weeks after the end of study drug treatment
- Occurrence of Major Amputations at 24 Weeks After the End of Study Drug TreatmentTime frame: At 24 weeks after the end of study drug treatment
Locations
78 sites in 6 countries. Site status is shown where the registry gives one.
404
Pilsen, Czechia
414
Ústí nad Labem, Czechia
1
Karlsbad, Germany
502
Aguascalientes, Mexico
505
Mérida, Mexico
501
Querétaro, Mexico
306
Bydgoszcz, Poland
321
Gmina Końskie, Poland
320
Krakow, Poland
314
Lublin, Poland
315
Lublin, Poland
316
Poznan, Poland
317
Poznan, Poland
301
Szczecin, Poland
304
Szczecin, Poland
307
Warsaw, Poland
308
Warsaw, Poland
309
Warsaw, Poland
318
Warsaw, Poland
319
Warsaw, Poland
312
Wroclaw, Poland
322
Zamość, Poland
246
Barnaul, Russia
205
Chelyabinsk, Russia
244
Chelyabinsk, Russia
228
Irkutsk, Russia
242
Kazan', Russia
227
Kemerovo, Russia
201
Moscow, Russia
202
Moscow, Russia
203
Moscow, Russia
209
Moscow, Russia
219
Moscow, Russia
220
Moscow, Russia
230
Moscow, Russia
248
Moscow, Russia
231
Novosibirsk, Russia
232
Novosibirsk, Russia
222
Omsk, Russia
217
Petrozavodsk, Russia
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.